DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clindamycin (Clindamycin Hydrochloride) - Indications and Dosage

 
 



Indications & Usage Section

Clindamycin hydrochloride capsules, USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.

 

Clindamycin hydrochloride capsules, USP are also indicated in the treatment of seri­ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the

WARNING

box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).

 

Anaerobes:

Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin­testinal tract); infections of the female pelvis and geni­tal tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection.

 

Streptococci:

Serious respiratory tract infections; seri­ous skin and soft tissue infections.

 

Staphylococci:

Serious respiratory tract infections; serious skin and soft tissue infections.

 

Pneumococci:

Serious respiratory tract infections.

 

Bacteriologic studies should be performed to deter­mine the causative organisms and their susceptibility to clindamycin.

 

To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacte­ria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

 

Dosage & Administration Section

If significant diarrhea occurs during therapy, this antibiotic should be discontinued (see

WARNING

box).

 

Adults

 

Serious infections

—150 to 300 mg every 6 hours.

More severe infections

—300 to 450 mg every 6 hours.

 

Pediatric Patients

 

Serious infections

—8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses.

More severe infections

—16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses.

 

To avoid the possibility of esophageal irritation, clindamycin hydrochloride capsules should be taken with a full glass of water.

Serious infections due to anaerobic bacteria are usu­ally treated with clindamycin injection. However, in clinically appropriate circum­stances, the physician may elect to initiate treatment or continue treatment with clindamycin hydrochloride capsules.

 

In cases of β-hemolytic streptococcal infections, treat­ment should continue for at least 10 days.

 

How Supplied Section

Clindamycin Hydrochloride Capsules USP, 150 mg

are light blue opaque/light green transparent size ‘1’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘C’ on light blue opaque cap and ‘39’ on light green transparent body with black ink.

 

                     Bottles of 100                         NDC 65862-185-01

                     Bottles of 500                         NDC 65862-185-05



Clindamycin Hydrochloride Capsules USP, 300 mg

are light blue opaque/light blue opaque size ‘0’ hard gelatin capsule filled with white to off-white powder and imprinted with ‘C’ on light blue opaque cap and ‘40’ on light blue opaque body with black ink.

 

                      Bottles of 16                             NDC 65862-

186

-16

                      Bottles of 100                           NDC 65862-186-01

                      Bottles of 500                           NDC 65862-186-05



Store at

20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].


Pharmacist:

Dispense in a tight container with child-resistant closure.

 

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017